FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312069968> ?p ?o ?g. }

• W4312069968 endingPage "31" @default.
• W4312069968 startingPage "31" @default.
• W4312069968 abstract "Combined ipilimumab and nivolumab significantly improve outcomes in metastatic melanoma patients but bear an important financial impact on the healthcare system. Here, we analyze the treatment costs, focusing on irAE. We conducted a retrospective analysis of 62 melanoma patients treated with ipilimumab-nivolumab at the Lausanne University Hospital between 1 June 2016 and 31 August 2019. The frequency of irAEs and outcomes were evaluated. All melanoma-specific costs were analyzed from the first ipilimumab-nivolumab dose until the therapy given subsequently or death. A total of 54/62 (87%) patients presented at least one irAE, and 31/62 (50%) presented a grade 3-4 irAE. The majority of patients who had a complete response 12/14 (86%) and 21/28 (75%) of overall responders presented a grade 3-4 toxicity, and there were no responses in patients without toxicity. Toxicity costs represented only 3% of the total expenses per patient. The most significant contributions were medication costs (44%) and disease costs (39%), mainly disease-related hospitalization costs, not toxicity-related. Patients with a complete response had the lowest global median cost per week of follow up (EUR 2425) and patients who had progressive disease (PD), the highest one (EUR 8325). Except for one patient who had a Grade 5 toxicity (EUR 6043/week), we observe that less severe toxicity grades (EUR 9383/week for Grade 1), or even the absence of toxicity (EUR 9922/week), are associated with higher median costs per week (vs. EUR 3266/week for Grade 4 and EUR 2850/week for Grade 3). The cost of toxicities was unexpectedly low compared to the total costs, especially medication costs. Patients with higher toxicity grades had better outcomes and lower total costs due to treatment discontinuation." @default.
• W4312069968 created "2023-01-04" @default.
• W4312069968 creator A5007749781 @default.
• W4312069968 creator A5009024807 @default.
• W4312069968 creator A5010663933 @default.
• W4312069968 creator A5019591142 @default.
• W4312069968 creator A5046496560 @default.
• W4312069968 creator A5048798659 @default.
• W4312069968 creator A5050031536 @default.
• W4312069968 creator A5051887638 @default.
• W4312069968 creator A5060002254 @default.
• W4312069968 creator A5071400586 @default.
• W4312069968 creator A5074293408 @default.
• W4312069968 creator A5082584620 @default.
• W4312069968 creator A5088528701 @default.
• W4312069968 date "2022-12-21" @default.
• W4312069968 modified "2023-10-01" @default.
• W4312069968 title "Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma" @default.
• W4312069968 cites W1965370740 @default.
• W4312069968 cites W2019607817 @default.
• W4312069968 cites W2128035403 @default.
• W4312069968 cites W2128758225 @default.
• W4312069968 cites W2133075384 @default.
• W4312069968 cites W2152897456 @default.
• W4312069968 cites W2491982852 @default.
• W4312069968 cites W2560367415 @default.
• W4312069968 cites W2572174216 @default.
• W4312069968 cites W2592144107 @default.
• W4312069968 cites W2736166064 @default.
• W4312069968 cites W2746148521 @default.
• W4312069968 cites W2753432434 @default.
• W4312069968 cites W2786816161 @default.
• W4312069968 cites W2886326580 @default.
• W4312069968 cites W2891205725 @default.
• W4312069968 cites W2896600825 @default.
• W4312069968 cites W2945590213 @default.
• W4312069968 cites W2954994190 @default.
• W4312069968 cites W3016810481 @default.
• W4312069968 cites W3043703771 @default.
• W4312069968 cites W3091417066 @default.
• W4312069968 cites W3155554393 @default.
• W4312069968 cites W3215580495 @default.
• W4312069968 doi "https://doi.org/10.3390/cancers15010031" @default.
• W4312069968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36612030" @default.
• W4312069968 hasPublicationYear "2022" @default.
• W4312069968 type Work @default.
• W4312069968 citedByCount "1" @default.
• W4312069968 countsByYear W43120699682023 @default.
• W4312069968 crossrefType "journal-article" @default.
• W4312069968 hasAuthorship W4312069968A5007749781 @default.
• W4312069968 hasAuthorship W4312069968A5009024807 @default.
• W4312069968 hasAuthorship W4312069968A5010663933 @default.
• W4312069968 hasAuthorship W4312069968A5019591142 @default.
• W4312069968 hasAuthorship W4312069968A5046496560 @default.
• W4312069968 hasAuthorship W4312069968A5048798659 @default.
• W4312069968 hasAuthorship W4312069968A5050031536 @default.
• W4312069968 hasAuthorship W4312069968A5051887638 @default.
• W4312069968 hasAuthorship W4312069968A5060002254 @default.
• W4312069968 hasAuthorship W4312069968A5071400586 @default.
• W4312069968 hasAuthorship W4312069968A5074293408 @default.
• W4312069968 hasAuthorship W4312069968A5082584620 @default.
• W4312069968 hasAuthorship W4312069968A5088528701 @default.
• W4312069968 hasBestOaLocation W43120699681 @default.
• W4312069968 hasConcept C121608353 @default.
• W4312069968 hasConcept C126322002 @default.
• W4312069968 hasConcept C141071460 @default.
• W4312069968 hasConcept C143998085 @default.
• W4312069968 hasConcept C167135981 @default.
• W4312069968 hasConcept C197934379 @default.
• W4312069968 hasConcept C2777658100 @default.
• W4312069968 hasConcept C2777701055 @default.
• W4312069968 hasConcept C2780030458 @default.
• W4312069968 hasConcept C2781433595 @default.
• W4312069968 hasConcept C29730261 @default.
• W4312069968 hasConcept C2994587330 @default.
• W4312069968 hasConcept C502942594 @default.
• W4312069968 hasConcept C71924100 @default.
• W4312069968 hasConceptScore W4312069968C121608353 @default.
• W4312069968 hasConceptScore W4312069968C126322002 @default.
• W4312069968 hasConceptScore W4312069968C141071460 @default.
• W4312069968 hasConceptScore W4312069968C143998085 @default.
• W4312069968 hasConceptScore W4312069968C167135981 @default.
• W4312069968 hasConceptScore W4312069968C197934379 @default.
• W4312069968 hasConceptScore W4312069968C2777658100 @default.
• W4312069968 hasConceptScore W4312069968C2777701055 @default.
• W4312069968 hasConceptScore W4312069968C2780030458 @default.
• W4312069968 hasConceptScore W4312069968C2781433595 @default.
• W4312069968 hasConceptScore W4312069968C29730261 @default.
• W4312069968 hasConceptScore W4312069968C2994587330 @default.
• W4312069968 hasConceptScore W4312069968C502942594 @default.
• W4312069968 hasConceptScore W4312069968C71924100 @default.
• W4312069968 hasIssue "1" @default.
• W4312069968 hasLocation W43120699681 @default.
• W4312069968 hasLocation W43120699682 @default.
• W4312069968 hasLocation W43120699683 @default.
• W4312069968 hasOpenAccess W4312069968 @default.
• W4312069968 hasPrimaryLocation W43120699681 @default.
• W4312069968 hasRelatedWork W2429247496 @default.

• next